Bd, techcyte announce strategic collaboration to offer ai-based digital cervical cytology system for pap testing

Ai-based algorithm aims to enable cytotechnologists and pathologists to efficiently identify evidence of cervical cancer and precancerous lesions franklin lakes, n.j. and orem, utah , jan. 30, 2024 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, and techcyte, a world leader in artificial intelligence (ai)-based digital diagnostics, today announced a strategic collaboration agreement to offer an ai-based algorithm that guides cytologists and pathologists to efficiently and effectively identify evidence of cervical cancer and precancer using whole-slide imaging.
BDX Ratings Summary
BDX Quant Ranking